Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...
Cystic fibrosis is a genetic disorder that affects roughly 40,000 Americans. The condition is caused by a mutation in the patient's cystic fibrosis transmembrane conductance regulator (CFTR) gene, ...
Boehringer headquarters Boehringer headquarters, Ingelheim, Germany Not intended for UK and US audiences JASCAYD® (nerandomilast) is the first oral, preferential PDE4B inhibitor approved in the ...
The cystic fibrosis market is expanding due to rising disease prevalence and advancements in targeted therapies and precision medicine. Predominantly affecting Western populations, over 30,000 people ...
The phase 2a MYLOX-1 trial demonstrated fibrosis reduction in some patients with myelofibrosis who previously received treatment with Jakafi (ruxolitinib). A phase 2a trial of novel monotherapy GB2064 ...
Cystic fibrosis affects many parts of the body, but its effects on the lungs can be especially harmful. Cystic fibrosis is a chronic and progressive condition that causes the mucus in your lungs to be ...
For most of the time we've known about cystic fibrosis, it's been a death sentence. But in the last decade, there have been incredible breakthroughs in treatment options that mean most p ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results